Prof. P.A. de Graeff, PhD

CHMP/ University Medical Center Groningen

 

Pieter de Graeff was born in 1950 and finished medical training at the University of Groningen in 1975. Following a training in internal medicine at the department op Internal Medicine of the UMCG he was registered as an internist in January 1983, practising  (part-time) until 2015. In 1983, he became a clinical advisor for the Dutch Medicines Evaluation Board (MEB), keeping a position as associate professor at the depts. of Internal Medicine and Pharmacology/Clinical Pharmacology. In 1989 he finished his thesis, titled “Effects of captopril on the heart. Mechanisms and Therapeutic Potentials.” In 1994 he was co-registered as a clinical pharmacologist. In 1996 he became Professor in Pharmacotherapeutics, responsible for implementing rational pharmacotherapy in the medical curriculum. In 2003 he was elected as “teacher of the year”. In 2000 he became head of the cardiovascular assessment team of the MEB and in 2007 he was elected as alternative member and in 2013 full member of the CHMP, the scientific committee of the EMA. Since 2013 he is also member of the MEB. He has fulfilled or still fulfils a number of positions at various organisations, among which the chairmanship of cardiovascular subgroup Working Party of the EMA (chairman since 2011), the Medical Ethics Committee of the UMCG, the Board of the Groningen Hypertension Service and the Board of the Dutch Society Clinical Pharmacology & Biopharmaceutics (chairman 1996-2000). He has (co-) authored more than 120 publications in peer-reviewed journals. He was involved in writing a number of regulatory cardiovascular guidelines, including those on antihypertensive, lipid-lowering and anti-arrhythmic agents.